DRUG (Bright Minds Biosciences) Beta: -19.2689 (As of Jun. 27, 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $65.79
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences Beta?

Bright Minds Biosciences DRUG +3.35% 34 Beta is -19.2689 as of Jun. 27, 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Bright Minds Biosciences's Beta is -19.2689.


Bright Minds Biosciences  (NAS:DRUG) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Bright Minds Biosciences Beta Related Terms


Bright Minds Biosciences Beta Historical Data

* Premium members only.

The historical data trend for Bright Minds Biosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Minds Biosciences Beta Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 1.59 -19.58

Bright Minds Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.03 -12.31 -19.58 -24.02 -17.67

DRUG vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Bright Minds Biosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Beta distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Beta falls into.


DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bright Minds Biosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -19.2689 mean?
Bright Minds Biosciences (DRUG) has a Beta of -19.2689 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' Beta too high?
Bright Minds Biosciences' current Beta is -19.2689. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Beta compare to VRTX and REGN?
Bright Minds Biosciences' Beta of -19.2689 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current Beta is -19.2689. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Beta of -19.2689. The current Beta is -19.2689. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Beta is -19.2689 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.79
Price